ATC Group: L01EE04 Selumetinib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01EE04 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01E Protein kinase inhibitors
4 L01EE Mitogen-activated protein kinase (MEK) inhibitors
5 L01EE04

Active ingredients in L01EE04

Active Ingredient Description
Selumetinib

Selumetinib is a selective inhibitor of mitogen activated protein kinase kinases 1 and 2 (MEK ½). Selumetinib blocks MEK activity and the RAF-MEK-ERK pathway. Therefore, MEK inhibition can block the proliferation and survival of tumour cells in which the RAF-MEK-ERK pathway is activated.

Related product monographs

Title Information Source Document Type  
KOSELUGO Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
KOSELUGO Hard capsule European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Brazil (BR)

Estonia (EE)

Finland (FI)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.